Discover how supplementing CHO cell cultures with high-quality Recombinant Insulin can improve and stabilize cell culture performance—ultimately driving higher monoclonal antibody (mAb) yields and lowering production costs.

The infographic below highlights key findings from a recent evaluation of insulin supplementation across different chemically defined media. Results demonstrate enhanced mAb productivity, consistent performance across insulin batches, and measurable economic benefits for biosimilar manufacturers aiming to match originator product quality while maintaining cost-efficiency.

Download the infographic in PDF format using the link at the bottom.